BioNTech SE - ADR BNTX shares were trading higher by 8.27% at $198.80 in Monday’s premarket session after the company announced a Chinese joint venture to make 1 billion COVID-19 vaccine doses.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases including COVID-19.
CureVac BV CVAC shares were trading higher by 5.08% at $105.50 amid reports that the company's COVID-19 vaccine is close to receiving European approval.
More than the COVID-19 vaccine, CureVac a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and pre-clinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
